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The five primary prostaglandins stimulate
contractions and phasic activity of the
urinary bladder urothelium, lamina propria
and detrusor
Zane Stromberga, Russ Chess-Williams and Christian Moro*
Abstract
Background: Inflammation is often associated with several bladder dysfunctions, including overactive bladder
(OAB) and interstitial cystitis/bladder pain syndrome (IC/PBS). As such, inflammation of the bladder and the actions
of inflammatory mediators may contribute to the development of urinary symptoms. This study assessed the
actions of PGE2, PGF2, PGD2, TXA2, and PGI2 on urinary bladder urothelium with lamina propria (U&LP), and detrusor
smooth muscle.
Methods: Studies were carried out using isolated tissue baths, where strips of porcine bladder U&LP or detrusor
were exposed to varying concentrations of prostaglandin agonists (1 μM and 10 μM).
Results: All assessed prostaglandin agonists contracted both the U&LP and detrusor smooth muscle, with the rank
order of contractile response effectiveness as: PGE2 > PGF2α > TXA2 > PGD2 > PGI2. In U&LP, treatment with PGE2
(10 μM) increased tonic contractions by 1.36 ± 0.09 g (n = 42, p < 0.001) and phasic contractions by 40.4 ± 9.6% (n =
42, p < 0.001). In response to PGF2α (10 μM), U&LP tonic contractions increased by 0.79 ± 0.06 g (n = 14, p < 0.001)
and phasic activity by 13.3% ± 5.3% (n = 15, p < 0.05). In detrusor preparations, PGE2 (10 μM) increased tonic
contractions by 1.32 ± 0.13 g (n = 38, p < 0.001) and PGF2α (10 μM) by 0.97 ± 0.14 g (n = 12, p < 0.001). Only 34% (n =
48) of all detrusor preparations exhibited spontaneous activity prior to the addition of any agonist at a frequency of
2.03 ± 0.12 cpm. In preparations that did not exhibit initial phasic activity, all of the prostaglandin agonists were
capable of commencing phasic activity.
Conclusions: The urinary bladder U&LP and detrusor respond to a variety of prostaglandin agonists, with their
activation resulting in direct contractions, as well as increases to spontaneous contractile activity. This study
presents the prostaglandin receptor system as a potential therapeutic target for lower urinary tract dysfunction.
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Background
The involvement of prostaglandins in bladder physiology
was first recognised from their release after urinary blad-
der distension or injury to the urothelium [1, 2]. An in-
crease of prostaglandins in the urine of patients
suffering from OAB has been well-reported previously
[3–6], suggesting the prostaglandin system as a potential
future therapeutic target in various bladder dysfunctions.
The exact role and mechanisms of endogenous prosta-
glandins in the urinary bladder are not well understood.
However, previous studies utilising exogenous prosta-
glandins have shown that these chemicals can alter con-
tractility and micturition reflex in human bladders [7].
Prostaglandin production is generally low in healthy
tissue but can increase immediately following acute in-
flammation [8]. They are synthesised in the bladder by
cyclooxygenase (COX) and then subsequently converted
into five primary prostanoids via their respective
synthases: PGE2, PGD2, PGF2α, prostacyclin (PGI2) and
thromboxane (TXA2) [9]. Prostaglandins are synthesised
in both the bladder urothelium with lamina propria
(U&LP) and in detrusor smooth muscle in response to
stretch, nerve stimulation, U&LP damage or other in-
flammatory mediators [10, 11]. The production of pros-
taglandins is determined by the cells present at sites of
inflammation capable of synthesising prostaglandins and
the activity of the two cyclooxygenase isoenzymes,
namely COX-1 and COX-2. For example, macrophages
predominantly generate PGE2 and TXA2, whereas mast
cells produce PGD2 [12]. COX-1 is present in most cells,
whereas the expression of COX-2 is generally low in
cells, but can increase dramatically upon stimulation by
immune cells [13]. Prostaglandin I2 is the main prosta-
glandin synthesised in the human bladder, followed by
PGE2, PGF2α and TXA2 [14, 15].
Although past studies have explored the effects of the
different prostaglandins on the urinary bladder with a
large focus on the actions of PGE2, a complete under-
standing of the contractile effects of the other four pros-
taglandins on the urinary bladder remain unclear.
Specifically, of interest is to determine how the actions
of the prostaglandins affect urothelium with lamina pro-
pria that is separated from the detrusor smooth muscle.
Therefore, this study aimed to assess the influence of
PGE2, PGF2α, PGD2, TXA2 and PGI2 on the urinary
bladder urothelium with lamina propria and detrusor
smooth muscle contractions and phasic activity.
Methods
Tissue preparation
Urinary bladders were obtained from Large White-
Landrace pigs (approximately six months old, weighing
between 80 and 100 kg) from the local abattoir after
slaughter for the routine commercial provision of food.
All methods were carried out in accordance with rele-
vant Australian guidelines and regulations, and all ex-
perimental protocols were in accordance the Australian
Code of Practice for the Care and Use of Animals for
Scientific Purpose [16]. As no animals were bred,
harmed, culled, interfered, or interacted with as part of
this research project, Animal Ethics Approval was not
required for offal use [17]. Urothelium with lamina pro-
pria was dissected from the underlying detrusor layer,
consistent with methods carried out in past studies [18–
21], and cut in strips. Adjacent strips of U&LP and de-
trusor (10 mm × 5mm) were tied vertically between an
isometric force transducer (MCT050/D, ADInstruments,
Castle Hill, Australia) and a fixed hook in 10mL organ
baths (Labglass, Brisbane, Australia), and superfused
with Krebs-bicarbonate solution (NaCl 118.4 mM,
NaHCO3 24.9 mM, CaCl2 1.9 mM, MgSO4 2.41 mM,
KCl 4.6 mM, KH2PO4 1.18 mM and D-glucose 11.7 mM)
and carbogen gas (95% oxygen and 5% carbon dioxide)
at 37 °C. After tissue mounting, strips of U&LP and de-
trusor were washed three times, tension adjusted to 1.5–
2.0 g and tissues left to equilibrate for 30 min. After the
equilibration period, a single dose of a prostaglandin re-
ceptor agonist was added to the tissue strip.
Pharmaceutical agents
The following compounds were used in this study: pros-
taglandin E2, prostaglandin F2α, prostaglandin D2, pros-
taglandin I2 and thromboxane A2 (U-46619, Cayman
Chemicals, Michigan, USA). Prostaglandin E2, prosta-
glandin F2α, prostaglandin D2, and prostaglandin I2 were
dissolved in 100% ethanol and diluted with distilled
H2O. U-46619 was supplied as a solution in methyl acet-
ate, which was diluted with distilled H2O. Two concen-
trations of each prostaglandin receptor agonists were
selected, 1 μM and 10 μM.
Data analysis
Data were graphed and analysed using GraphPad Prism
version 8.3 for Windows (GraphPad Software, La Jolla,
California, USA). Statistical analysis was conducted using
a paired Student’s t-test, where p < 0.05 was considered
as significant. All values were reported as mean change
± SEM. n equates to the number of individual bladders
used in this study.
Results
Prostaglandin agonists for increasing U&LP spontaneous
phasic activity
Strips of U&LP exhibited spontaneous phasic contrac-
tions in the absence of any stimulation at a mean fre-
quency of 3.26 ± 0.07 cycles per minute (cpm, n = 146).
Treatment with PGE2 caused the most prominent in-
creases to U&LP spontaneous contractile activity. When
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PGE2 (1 μM) was added to isolated tissues, spontaneous
activity increased by 39.2% ± 6.7% (n = 38, p < 0.001,
Fig. 1). A greater concentration of PGE2 (10 μM) showed
similar increases of 40.4% ± 9.6% to the U&LP spontan-
eous activity (n = 42, p < 0.001). Treatment with PGF2α
showed smaller increases of 10.5% ± 4.6% to spontaneous
activity when treated with 1 μM (n = 10, p < 0.05) and
13.3% ± 5.3% when treated with 10 μM (n = 14, p < 0.05).
The addition of PGI2 (10 μM) increased spontaneous ac-
tivity by 6.2% ± 1.6% (n = 8, p < 0.01) but had no effect at
a lower concentration (1 μM, n = 8). The frequency was
not significantly affected by PGD2 (1–10 μM, n = 12) or
TXA2 (1–10 μM, n = 16).
The average amplitude of these spontaneous phasic
contractions exhibited in U&LP strips in the absence of
any stimulation was 0.57 ± 0.02 g (n = 146). In response
to treatment with 1 μM PGE2, amplitude decrease of
0.14 ± 0.04 g (n = 38, p < 0.001, Table 1) were observed.
Similar decreases of 0.16 ± 0.03 g were also observed in
response to a higher PGE2 concentration (10 μM, n = 42,
p < 0.01). Treatment with TXA2 (1 μM) showed a sig-
nificant decrease in the amplitude by 0.28 ± 0.06 g
(n = 8, p < 0.01), which was not observed at a higher
concentration (10 μM, n = 6). The addition of PGI2
(10 μM) decreased amplitude of spontaneous activity
by 0.14 ± 0.05 (n = 8, p < 0.05) but had no effect at a
lower concentration (1 μM, n = 8). The amplitude of
spontaneous contractions was not altered by the
addition of either PGF2α (1–10 μM, n = 24) or PGD2
(1–10 μM, n = 12, Table 1). None of the decreases in
the amplitude of spontaneous phasic contractions of
the U&LP were significantly affected by the two dif-
ferent prostaglandin receptor agonist concentrations
(1 μM and 10 μM).
Prostaglandin agonists in stimulating phasic contractions
in detrusor
Total of 34% (n = 48) of the detrusor preparations that
were set up in the organ baths exhibited spontaneous ac-
tivity prior to the addition of any agonists. These
Fig. 1 U&LP changes in the frequency of spontaneous phasic contractions after the treatment with 1 μM and 10 μM of each specific
prostaglandin agonists E2, F2α, TXA2, D2, and I2. There were no statistically significant differences in frequency changes between the 1 μM and
10 μM concentrations for any of the agonists (unpaired Student’s 2-tailed t-test)
Table 1 U&LP changes in the amplitude of phasic contractions in response to the five primary prostaglandin agonists (mean ± SEM)
1 μM of agonist 10 μM of agonist
Agonist Absence (g) Presence (g) n Absence (g) Presence (g) n
PGE2 0.53 ± 0.05 0.40 ± 0.03*** 38 0.53 ± 0.04 0.37 ± 0.03** 42
PGF2α 0.30 ± 0.03 0.29 ± 0.01 10 0.51 ± 0.06 0.46 ± 0.08 14
TXA2 0.90 ± 0.16 0.62 ± 0.14** 8 0.75 ± 0.16 0.71 ± 0.25 6
PGD2 0.59 ± 0.10 0.46 ± 0.04 4 0.55 ± 0.08 0.43 ± 0.06 8
PGI2 0.64 ± 0.07 0.56 ± 0.07 8 0.57 ± 0.09 0.43 ± 0.06* 8
*p < 0.05, **p < 0.01, ***p < 0.001. Paired Student’s t-test
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contractions occurred at an average frequency of 2.03 ±
0.12 cpm (n = 48) with an average amplitude of 0.26 ±
0.02 g (n = 48). However, the majority of the detrusor
preparations, that were otherwise quiescent developed
spontaneous phasic contractions after the addition of
the agonist.
Of those detrusor preparations that did not exhibit ini-
tial phasic activity during baseline: PGE2 (1 μM) sparked
contractions in 68% of preparations (n = 19) and PGE2
(10 μM) in 69% (n = 22); PGF2α (1 μM) initiated contrac-
tions in in 56% (n = 5) and PGF2α (10 μM) in 88% (n =
7); TXA2 (1 μM) initiated contractions in 63% (n = 5)
and TXA2 (10 μM) in 80% (n = 4); PGD2 (1 μM) initiated
phasic activity in 50% (n = 2) and PGD2 (10 μM) in 75%
(n = 6); and lastly PGI2 (10 μM) initiated contractions in
40% (n = 2) of preparations. This demonstrates the abil-
ity of prostaglandin agonists to induce spontaneous ac-
tivity in otherwise quiescent detrusor tissue strips.
Prostaglandin agonists in stimulating tonic contractions
in U&LP
All assessed prostaglandin agonists contracted the U&LP
with the rank order of contractile response effectiveness
as: PGE2 > PGF2α > TXA2 > PGD2 > PGI2. The addition of
PGE2 (1 μM) to isolated U&LP induced tissue contrac-
tions, with increases of 1.01 ± 0.08 g (n = 38, p < 0.001) to
the tonic contractions. When a greater concentration of
PGE2 (10 μM) was selected, increases of 1.36 ± 0.09 g (n =
42, p < 0.001, Fig. 2) were observed. Treatment with 1 μM
PGF2α showed a small increase to tonic contractions of
0.15 ± 0.04 g (n = 10, p < 0.01) when compared to a higher
concentration of 10 μM, which exhibited increases of
0.79 ± 0.06 g (n = 14, p < 0.001). The addition of two con-
centrations of TXA2 induced similar contractions, where
tonic contraction increased by 0.70 ± 0.07 g when treated
with 1 μM (n = 8, p < 0.001), and by 0.65 ± 0.12 g after
treatment with 10 μM (n = 6, p < 0.001).
Fig. 2 U&LP changes in tonic contractions in response to the treatment with 1 μM and 10 μM of prostaglandin E2 (top row), F2α (middle row) and
TXA2 (bottom row). Sample traces of the responses observed to two concentrations of prostaglandin agonist (left & middle columns). Increases in
tonic contractions after treatment with each agonist are represented as mean change ± SEM (right column). Significant changes in the tonic
contractions between 1 μM and 10 μM were evaluated using an unpaired Student’s two-tailed t-test, where *p < 0.05, **p < 0.01, ***p < 0.001
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When PGD2 (1 μM) was added to the U&LP tissue
preparations, tonic contractions increased by 0.19 ± 0.04
g (n = 4, p < 0.05, Fig. 3). Treatment with a higher con-
centration of PGD2 (10 μM) exhibited increases of
0.63 ± 0.09 g (n = 8, p < 0.001). The addition of PGI2
showed small increases in tonic contractions of 0.11 ±
0.02 g in response to 1 μM PGI2 (n = 8, p < 0.001), and
0.22 ± 0.03 g in response to 10 μM PGI2 (n = 8, p < 0.001,
Fig. 3).
Prostaglandin agonists in stimulating tonic contractions
in detrusor
All assessed prostaglandin agonists contracted the de-
trusor smooth muscle preparations with the rank order
of contractile response effectiveness as: PGE2 > PGF2α >
TXA2 > PGD2 > PGI2. In detrusor preparations, PGE2
(1 μM) increased the tonic contractions by 0.73 ± 0.09 g
(n = 34, p < 0.001), whereas PGE2 (10 μM) nearly doubled
the response, producing an average increase of 1.32 ±
0.13 g (n = 38, p < 0.001, Fig. 4). Treatment with 1 μM
PGF2α showed a small increase of 0.20 ± 0.05 g (n = 10,
p < 0.01), whereas 10 μM of PGF2α increased the tonic
contractions by 0.97 ± 0.14 g (n = 12, p < 0.001). When
TXA2 was added, tonic contractions increased by 0.47 ±
0.12 g when treated with 1 μM (n = 8, p < 0.001), and by
1.03 ± 0.14 g (n = 6, p < 0.001, Fig. 4) when treated with
1 μM TXA2.
PGD2 showed a small increase in the tonic contrac-
tions of 0.12 ± 0.04 g when 1 μM was added (n = 4, p <
0.05), and an increase of 0.36 ± 0.06 g when 10 μM PGD2
was added (n = 6, p < 0.01, Fig. 5). PGI2 showed small in-
creases in tonic contractions at both concentrations,
showing an increase of 0.16 ± 0.02 g when treated with
1 μM (n = 8, p < 0.001), and 0.13 ± 0.03 g when treated
with 10 μM PGI2 (n = 8, p < 0.001, Fig. 5). The effects of
prostaglandin agonists on tonic contractions of the de-
trusor smooth muscle were significantly different be-
tween the two concentrations (1 μM and 10 μM) for
PGE2 (p < 0.001), PGF2α (p < 0.001) and PGD2 (p < 0.05).
Discussion
Previous research has shown that stimulation of the M3
muscarinic receptor in U&LP causes immediate contrac-
tions, as well as increases in the frequency of spontan-
eous phasic contractions, and reduction in their
amplitude [22, 23]. In our study, the prostaglandin ago-
nists have shown similar contractile responses to both
tonic contractions and spontaneous activity, thereby as-
sociating the actions of prostaglandins with many of the
bladder contractile dysfunctions, such as OAB and IC/
BPS.
The ability to contract the tissue was varied between
the different prostaglandin agonists. The rank order of
agonist response in stimulating contractions in U&LP
and detrusor was: PGE2 > PGF2α > TXA2 > PGD2 > PGI2.
This furthers previous research which reported the in-
volvement of PGE2 in the initiation of micturition in
both humans and animals [24], suggesting a contribution
Fig. 3 U&LP changes in tonic contractions in response to the treatment with 1 μM and 10 μM of prostaglandin agonists D2 (top row) and I2
(bottom row). Sample traces of the responses observed to two concentrations of prostaglandin agonist (left & middle columns). Increases in tonic
contractions after treatment with each agonist are represented as mean change ± SEM (right column). Significant changes in the tonic
contractions between 1 μM and 10 μM were evaluated using an unpaired Student’s two-tailed t-test, where *p < 0.05, **p < 0.01, ***p < 0.001
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to bladder overactivity. Treatment with PGF2α showed
minimal increases at a concentration of 1 μM, yet re-
sponses were significantly enhanced in both U&LP and
detrusor when increased to 10 μM. At the smaller con-
centration of 1 μM, treatment with TXA2 reached max-
imal contractile responses, and as such, was not
enhanced at the higher agonist concentration of 10 μM.
This was not the case with detrusor preparations,
wherein the higher concentration of TXA2 (10 μM) re-
sulted in significantly enhanced contractions. The re-
sponses observed in porcine tissue in response to PGF2α,
and TXA2 are consistent with the Palea [25] findings. In
addition, our study has established that U&LP isolated
tissue is also capable of responding and producing defin-
ite increases in tonic contractions in response to these
prostaglandin agonists.
Of the five prostaglandins, PGD2 and PGI2 had the
smallest effect on both tonic contractions and
spontaneous activity. This lack of increases to the tonic
contractions or spontaneous contractile frequency may
be explained by PGD2 having potential inhibitory actions
via the stimulation of DP receptor [26]. An explanation
for the small contractile effects observed in our study in
response to PGI2, the main prostaglandin synthesised in
the human bladder [14, 27], is that the aqueous solutions
of PGI2 are extremely chemically unstable with a rela-
tively short half-life, depending on the buffer concentra-
tion [28]. As such, future studies utilising more
chemically stable PGI2 agonist analogous might provide
further insights into the actions of this inflammatory
mediator on the urinary bladder.
Conclusions
The urinary bladder is capable of responding to all five
major prostaglandins produced in the urinary bladder.
Out of these prostaglandins, PGE2 and PGF2α had the
Fig. 4 Detrusor changes in tonic contractions in response to the treatment with 1 μM and 10 μM of prostaglandin E2 (top row), F2α (middle row)
and TXA2 (bottom row). Sample traces of the responses observed to two concentrations of prostaglandin agonist (left & middle columns). Increases
in tonic contractions after treatment with each agonist are represented as mean change ± SEM (right column). Significant changes in the tonic
contractions between 1 μM and 10 μM were evaluated using an unpaired Student’s two-tailed t-test, where *p < 0.05, **p < 0.01, ***p < 0.001
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most significant impact on both contraction and in-
creases to the spontaneous contractile frequency in the
U&LP. All five prostaglandin receptor agonists were also
capable of inducing spontaneous phasic contractions in
otherwise quiescent detrusor tissue strips.
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